Literature DB >> 25048157

Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy.

Brian C Callaghan1, Kevin A Kerber1, Lynda L Lisabeth1, Lewis B Morgenstern1, Ruth Longoria1, Ann Rodgers1, Paxton Longwell2, Eva L Feldman1.   

Abstract

IMPORTANCE: Distal symmetric polyneuropathy (DSP) is a prevalent condition that results in high costs from diagnostic testing. However, the role of neurologists and diagnostic tests in patient care is unknown.
OBJECTIVE: To determine how often neurologists and diagnostic tests influence the diagnosis and management of DSP in a community setting. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, we used a validated case-capture method (International Classification of Diseases, Ninth Revision screening technique with subsequent medical record abstraction) to identify all patients with a new DSP diagnosis treated by community neurologists in Nueces County, Texas, who met the Toronto Diabetic Neuropathy Expert Group consensus criteria for probable DSP. Using a structured data abstraction process, we recorded diagnostic test results, diagnoses rendered (before and after testing), and subsequent management from April 1, 2010, through March 31, 2011. MAIN OUTCOMES AND MEASURES: Changes in DSP cause and management after diagnostic testing by neurologists.
RESULTS: We identified 458 patients with DSP followed up for a mean (SD) of 435.3 (44.1) days. Neurologists identified a cause of DSP in 291 patients (63.5%) before their diagnostic testing. Seventy-one patients (15.5%) had a new DSP cause discovered after testing by neurologists. The most common new diagnoses were prediabetes (28 [6.1%]), vitamin B12 deficiency (20 [4.4%]), diabetes mellitus (8 [1.7%]), and thyroid disease (8 [1.7%]). Management changes were common (289 [63.1%]) and usually related to neuropathic pain management (224 [48.9%]). A potential disease-modifying management change was made in 113 patients (24.7%), with the most common changes being diabetes management in 45 (9.8%), treatment with vitamins in 39 (8.5%), diet and exercise in 33 (7.2%), and adjustment of thyroid medications in 10 (2.2%). Electrodiagnostic testing and magnetic resonance imaging of the neuroaxis rarely led to management changes. CONCLUSIONS AND RELEVANCE: Neurologists diagnosed the cause of DSP in nearly two-thirds of patients before their diagnostic testing. Inexpensive blood tests for diabetes, thyroid dysfunction, and vitamin B12 deficiency allowed neurologists to identify a new cause of DSP in 71 patients (15.5%). In contrast, expensive electrodiagnostic tests and magnetic resonance imaging rarely changed patient care.

Entities:  

Mesh:

Year:  2014        PMID: 25048157      PMCID: PMC4266395          DOI: 10.1001/jamaneurol.2014.1279

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  28 in total

1.  Tests and expenditures in the initial evaluation of peripheral neuropathy.

Authors:  Brian Callaghan; Ryan McCammon; Kevin Kerber; Xiao Xu; Kenneth M Langa; Eva Feldman
Journal:  Arch Intern Med       Date:  2012-01-23

2.  Capturing cases of distal symmetric polyneuropathy in a community.

Authors:  Brian Callaghan; Kevin Kerber; Ruth Longoria; Eva Feldman; Lynda Lisabeth
Journal:  Muscle Nerve       Date:  2012-10-05       Impact factor: 3.217

3.  Economics of neurology 101: The dismal science meets the dismal prognosis.

Authors:  John P Ney; Marc R Nuwer
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

4.  Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.

Authors:  J R Singleton; A G Smith; M B Bromberg
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

5.  The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice.

Authors:  Brian C Callaghan; Kevin Kerber; Andrea L Smith; A Mark Fendrick; Eva L Feldman
Journal:  Arch Neurol       Date:  2011-11-14

Review 6.  Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.

Authors:  J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D N Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner
Journal:  Neurology       Date:  2008-12-03       Impact factor: 9.910

7.  Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group.

Authors:  G Savettieri; W A Rocca; G Salemi; F Meneghini; F Grigoletto; L Morgante; A Reggio; V Costa; M A Coraci; R Di Perri
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

8.  Prevalence of peripheral neuropathy in the Parsi community of Bombay.

Authors:  N E Bharucha; A E Bharucha; E P Bharucha
Journal:  Neurology       Date:  1991-08       Impact factor: 9.910

9.  Influence of physician specialty on outcomes after acute ischemic stroke.

Authors:  Leslie Allison Gillum; S Claiborne Johnston
Journal:  J Hosp Med       Date:  2008-05       Impact factor: 2.960

10.  Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey.

Authors:  Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

View more
  20 in total

1.  Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy.

Authors:  Magdalena Lang; Roi Treister; Anne Louise Oaklander
Journal:  J Neurol       Date:  2016-10-11       Impact factor: 4.849

2.  The hidden costs of painful diabetic neuropathy revealed.

Authors:  A Gordon Smith; Saša Živković
Journal:  Neurol Clin Pract       Date:  2019-10-29

3.  Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status.

Authors:  Brian C Callaghan; Rong Xia; Mousumi Banerjee; Nathalie de Rekeneire; Tamara B Harris; Anne B Newman; Suzanne Satterfield; Ann V Schwartz; Aaron I Vinik; Eva L Feldman; Elsa S Strotmeyer
Journal:  Diabetes Care       Date:  2016-03-10       Impact factor: 19.112

4.  Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls.

Authors:  Brian Callaghan; Kevin Kerber; Kenneth M Langa; Mousumi Banerjee; Ann Rodgers; Ryan McCammon; James Burke; Eva Feldman
Journal:  Neurology       Date:  2015-05-27       Impact factor: 9.910

5.  Electrodiagnostic tests are unlikely to change management in those with a known cause of typical distal symmetric polyneuropathy.

Authors:  Brian C Callaghan; James F Burke; Kevin A Kerber; James W Albers; Eva L Feldman
Journal:  Muscle Nerve       Date:  2017-06-22       Impact factor: 3.217

Review 6.  Distal Symmetric Polyneuropathy: A Review.

Authors:  Brian C Callaghan; Raymond S Price; Eva L Feldman
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

7.  Overcoming barriers to diabetic polyneuropathy management in primary care.

Authors:  Alyce S Adams; Brian Callaghan; Richard W Grant
Journal:  Healthc (Amst)       Date:  2016-12-07

Review 8.  Neurologic examination in the elderly.

Authors:  Navid Seraji-Bzorgzad; Henry Paulson; Judith Heidebrink
Journal:  Handb Clin Neurol       Date:  2019

9.  Neuroimaging overuse is more common in Medicare compared with the VA.

Authors:  James F Burke; Eve A Kerr; Ryan J McCammon; Rob Holleman; Kenneth M Langa; Brian C Callaghan
Journal:  Neurology       Date:  2016-07-08       Impact factor: 9.910

Review 10.  Diabetic neuropathy: what does the future hold?

Authors:  Brian C Callaghan; Gary Gallagher; Vera Fridman; Eva L Feldman
Journal:  Diabetologia       Date:  2020-01-23       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.